According to Voice of China << peak evening news >> reported that Shanghai started last April from H7N9 avian influenza vaccine research, has successfully developed H7N9 vaccine is expected to be finalized next month, the fastest antibody screening, has entered clinical trials, but experts say According to regulations, the actual conduct of the last two years may have little clinical use.
These days, autoimmune attack toxicity evaluation Shanghai H7N9 avian influenza DNA vaccine reported freshly baked, dozens were injected DNA vaccine in mice, and then implanted H7N9 avian influenza virus, 30 days no one died, no one found to be infected with pathogenic virus, the effectiveness of the vaccine was initially confirmed. Shanghai New Hair Institute and professor of infectious diseases reproduction Xu Jianqing told reporters last April, H7N9 bird flu outbreak in the country, when the number of domestic units start vaccine development.
Xu Jianqing: vaccine against H7N9 avian influenza in general have different technical route, which has been the traditional technology roadmap inactivated when we do adopt another technology route is through the means of genetic engineering technology roadmap.
Try to implant the main causative gene H7N9 vaccine vectors to mature, the equivalent of deposit into the safe and then into human cells, because the protein structure of the virus inactivation process has not been destroyed, they stimulate the body to produce an effective immune response.
Xu Jianqing: A total of four test batches of mice after the kick vaccine in mice, we further with live H7N9 virus to attack, to infect mice vaccinated after infection found that these mice are still well protected, always. They did not die of it, no disease, there is only a slight weight loss.
It can be said Shanghai H7N9 avian influenza vaccine has achieved initial success. So when are we going to use the H7N9 bird flu vaccine it? Xu Jianqing said the vaccine typically go through three stages.
Xu Jianqing: The first stage is the development stage, so that it is effective in animals which is the second part of a clinical trial to prepare for the main time is spent in the clinical evaluation of regulations, it has a specific time for observation. .. because you have to prove that the vaccine first to exclude it harmless, regulations have clearly defined what indicators do observe it, prove it harmless.
It is understood that, in accordance with China's relevant laws, a new vaccine to spend time on the clinical validation of evaluation is probably 5-6 years, but Xu Jianqing noted, appeared in 2009 when the H1N1 flu, also had to make an exception in advance of the clinical application of precedent.
Xu Jianqing: 2009 H1N1 vaccine when it quickly when the ground is because the clinical needs of emergency was still a lot of people criticize the government, because it does not follow the normal regulatory requirements actually go so governments also have similar .. the case is in particular the case of more urgent disease is allowed speed, the vaccine clinical use.
But for the current H7N9 situation presents distribute, Xu Jianqing think they recently developed a vaccine is unlikely to be used in clinical practice.
We are also tracking down its variation, if the epidemic is really serious, you may follow the government regulations on the fast track to go, maybe a year we might have hoped, but this sporadic cases of this in the current situation: Xu Jianqing the possibility of entering the fast lane is not very large. unless there is clear evidence that there is actually someone successor, I believe our government will consider this matter.
Source: Word News